# Biocodex

Biocodex is an other based in Gentilly, France.

## Overview

- **Organization type:** other
- **Headquarters:** Gentilly, France
- **Region:** Europe
- **Address:** Gentilly, France
- **Founded:** 1953
- **Assets under management:** Undisclosed
- **Website:** www.biocodex.com
- **LinkedIn:** https://www.linkedin.com/company/biocodex

## Regulatory record

- **Reports private funds:** No

## About

Biocodex is a French pharmaceutical company founded in 1953. The family-owned business has expanded its portfolio into Gastroenterology, Pain management, Neurology/Psychiatry, Otolaryngology, and Rheumatology. Biocodex has made 9 investments, including a PIPE investment in MaaT Pharma on November 13, 2025, and has exited one portfolio company, MaaT Pharma, on November 03, 2021.

## Sectors

- Healthcare Services
- Pharmaceuticals
- Biotechnology

## People

- Jean-Pierre Tabet — CEO
- Benoit Thiron — Chief Financial Officer

## Questions

### Who controls Biocodex?

Biocodex is privately owned by the founding family. The company's CEO, Jean-Pierre Tabet, leads day-to-day operations, and the board reflects family control. No external shareholders or private equity investors hold a stake (public record).

### What is Biocodex's main therapeutic focus?

The firm specializes in microbiome science, particularly probiotics and gastrointestinal health. Its flagship product, Floré, is one of the most widely distributed probiotics globally. Biocodex also markets prescription medications for pain and central nervous system disorders (public record).

### What is Biocodex's geographic footprint?

Headquartered in Gentilly, France, Biocodex operates in over 100 countries, with manufacturing in France and commercial offices across Europe, Asia, Africa, and the Americas. The firm has a particularly strong presence in European and North American markets (public record).

### How does Biocodex approach research and development?

The firm invests heavily in clinical research for microbiome-based therapeutics. It conducts its own R&D and collaborates with academic institutions and research organizations globally. Recent efforts have focused on expanding the evidence base for probiotics in immune and digestive health (public record).

## Related profiles

- [PTC Inc.](https://altss.com/profile/ptc-inc)
- [Airbus S.A.S.](https://altss.com/profile/airbus-sas)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/biocodex

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology